Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and <i>in vivo</i> response to cabergoline therapy

Leonardo Vieira Neto, Luiz Eduardo Wildemberg, Aline Barbosa Moraes, Leandro M. Colli, Leandro Kasuki, Nelma Verônica Marques, Emerson L. Gasparetto, Margaret de Castro, Christina Maeda Takiya, Mônica R. Gadelha

Clinical Endocrinology · 2014 · 63 citations · 30 references

Abstract

In conclusion, DR2 is expressed in all adenomas and the majority of the patients in this study displayed tumour shrinkage on cabergoline (CAB) therapy. Thus, CAB might be useful in adjuvant therapy in NFPA patients with residual tumours after surgery.

References

30